Drug Profile
Rontalizumab
Alternative Names: PRO155767; RG 7415; rhuMAb IFN alphaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genentech
- Developer Chugai Pharmaceutical; Genentech
- Class Monoclonal antibodies
- Mechanism of Action Interferon alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Systemic lupus erythematosus
Most Recent Events
- 24 Jul 2014 Discontinued - Phase-II for Systemic lupus erythematosus in USA, United Kingdom, Colombia, Poland and Russia (IV)
- 24 Jul 2014 Discontinued - Phase-II for Systemic lupus erythematosus in USA, United Kingdom, Colombia, Poland and Russia (SC)
- 01 Apr 2014 Discontinued - Phase-I for Systemic lupus erythematosus in Japan (Parenteral)